Predictors and implications of early left ventricular ejection fraction improvement in new-onset idiopathic nonischemic cardiomyopathy with narrow QRS complex: A NEOLITH substudy

Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
Norman C WangSamir Saba

Abstract

Predictors and implications of early left ventricular ejection fraction (LVEF) improvement with guideline-directed medical therapy (GDMT) in new-onset idiopathic nonischemic cardiomyopathy (NICM) with narrow QRS complex are not well described. The objectives were to describe predictors of LVEF improvement after 3 months on GDMT and adverse cardiac events based on post-GDMT LVEF status (≤35% vs. >35%). A retrospective cohort study was performed in subjects with new-onset NICM, LVEF ≤35%, and narrow QRS complex. Associations for baseline variables with post-GDMT LVEF improvement and absolute change in LVEF (∆LVEFGDMT ) were assessed. Cox proportional hazards models assessed associations for post-GDMT LVEF status with adverse cardiac events. In 70 subjects, 31 (44%) had post-GDMT LVEF ≤35% after a median follow-up time of 97.5 days (interquartile range, 84-121 days). In final multivariable models, severely dilated left ventricular end-diastolic diameter (LVEDD), compared with normal LVEDD, strongly predicted post-GDMT LVEF ≤35% (odds ratio, 7.77; 95% confidence interval [CI], 1.39-43.49; p = .02) and ∆LVEFGDMT (β = -15.709; standard error = 4.622; p = .001). Subjects with post-GDMT LVEF ≤35% were more likely to have adverse cardia...Continue Reading

References

May 21, 2004·The New England Journal of Medicine·Alan KadishUNKNOWN Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators
Jan 22, 2005·The New England Journal of Medicine·Gust H BardyUNKNOWN Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators
Dec 7, 2005·Circulation·Scott D SolomonUNKNOWN Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators
Feb 8, 2006·Circulation·Kenneth A EllenbogenUNKNOWN Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators
Jun 20, 2006·Journal of the American College of Cardiology·Alan KadishJoseph Levine
Sep 12, 2007·Circulation·Robert A Kloner, Shereif H Rezkalla
Jun 12, 2008·JAMA : the Journal of the American Medical Association·Norman C WangUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Feb 21, 2013·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Jorge E SchliamserUNKNOWN DEFINITE Investigators
Mar 7, 2013·JAMA : the Journal of the American Medical Association·Ankur GulatiSanjay K Prasad
Jun 12, 2013·Journal of the American College of Cardiology·Clyde W YancyUNKNOWN American Heart Association Task Force on Practice Guidelines
Jan 7, 2015·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·Roberto M LangJens-Uwe Voigt
Aug 2, 2015·Journal of the American Heart Association·Ryan G AleongBarry London
Dec 17, 2015·Journal of the American College of Cardiology·Madhurmeet SinghEvan C Adelstein
Mar 30, 2016·Circulation·Jonathan P PicciniUNKNOWN American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology and Council o
Aug 30, 2016·The New England Journal of Medicine·Lars KøberUNKNOWN DANISH Investigators

❮ Previous
Next ❯

Citations

Nov 27, 2019·Pacing and Clinical Electrophysiology : PACE·Amr F BarakatSamir Saba

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.